Valiant Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 543998 | NSE: VALIANTLAB | Pharmaceuticals & Drugs | Small Cap

Valiant Laboratories Share Price

157.15 0.10 0.06%
as on 29-Apr'24 13:40

DeciZen - make an informed investing decision on Valiant Laboratories

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Valiant Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
23.53
Market Cap:
682.4 Cr.
52-wk low:
140
52-wk high:
227

Is Valiant Laboratories Ltd an attractive stock to invest in?

1. Is Valiant Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Valiant Laboratories Ltd is a below average quality company.

2. Is Valiant Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Valiant Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Valiant Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Valiant Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Valiant Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Valiant Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'22Mar'23TTM
ROCE % 20.3%19.7%-
Value Creation
Index
0.50.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 292334334
Sales YoY Gr.-14.5%-
Adj EPS 8.28.86.7
YoY Gr.-6.7%-
BVPS (₹) 2230.958.6
Adj Net
Profit
26.828.629
Cash Flow from Ops. 2.323-
Debt/CF from Ops. 272.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANANA14.5%
Adj EPS NANANA6.7%
BVPSNANANA40.6%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'22Mar'23TTM
Return on
Equity %
37.533.314.9
Op. Profit
Mgn %
14.510.55
Net Profit
Mgn %
9.28.68.7
Debt to
Equity
0.90.6-
Working Cap
Days
015668
Cash Conv.
Cycle
06850

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 14.90%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at -18.76%

Latest Financials - Valiant Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 6.7 6.7
TTM Sales (₹ Cr.) 334 334
BVPS (₹.) 58.6 58.6
Reserves (₹ Cr.) 211 211
P/BV 2.68 2.68
PE 23.53 23.53
From the Market
52 Week Low / High (₹) 139.95 / 226.95
All Time Low / High (₹) 139.95 / 226.95
Market Cap (₹ Cr.) 682
Equity (₹ Cr.) 43.5
Face Value (₹) 10
Industry PE 48.8

Management X-Ray of Valiant Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Valiant Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23
Sales292334
Operating Expenses 249299
Manufacturing Costs813
Material Costs234277
Employee Cost 35
Other Costs 45
Operating Profit 4235
Operating Profit Margin (%) 14.5%10.5%
Other Income 25
Interest 00
Depreciation 22
Exceptional Items 00
Profit Before Tax 4238
Tax 149
Profit After Tax 2729
PAT Margin (%) 9.4%8.7%
Adjusted EPS (₹)8.48.9
Dividend Payout Ratio (%)0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23

Equity and Liabilities

Shareholders Fund 71100
Share Capital 1633
Reserves 5568
Minority Interest00
Debt6159
Long Term Debt5959
Short Term Debt10
Trade Payables4647
Others Liabilities 36
Total Liabilities 182213

Fixed Assets

Gross Block3039
Accumulated Depreciation89
Net Fixed Assets2230
CWIP 10
Investments 034
Inventories1613
Trade Receivables11189
Cash Equivalents 200
Others Assets1147
Total Assets 182213

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23
Cash Flow From Operating Activity 223
PBT 4238
Adjustment 32
Changes in Working Capital -28-8
Tax Paid -14-9
Cash Flow From Investing Activity -12-21
Capex -7-7
Net Investments 0-34
Others -520
Cash Flow From Financing Activity 6-2
Net Proceeds from Shares 490
Net Proceeds from Borrowing 00
Interest Paid -10
Dividend Paid 00
Others -42-1
Net Cash Flow -40
PARTICULARSMar'22Mar'23
Ratios
ROE (%)38.4828.86
ROCE (%)31.6224.01
Asset Turnover Ratio1.61.57
PAT to CFO Conversion(x)0.070.79
Working Capital Days
Receivable Days13997
Inventory Days2014
Payable Days7262

Valiant Laboratories Ltd Stock News

Valiant Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Valiant Laboratories on 29-Apr-2024 13:40 is ₹157.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2024 13:40 the market cap of Valiant Laboratories stood at ₹682.4.
The latest P/E ratio of Valiant Laboratories as of 29-Apr-2024 13:40 is 23.53.
The latest P/B ratio of Valiant Laboratories as of 29-Apr-2024 13:40 is 2.68.
The 52-week high of Valiant Laboratories is ₹226.9 and the 52-week low is ₹139.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Valiant Laboratories is ₹333.9 ( Cr.) .

About Valiant Laboratories Ltd

Valiant Laboratories was originally formed as a partnership firm under the name and style of ‘M/s. Bharat Chemicals’ pursuant to the deed of partnership dated October 17, 1980, amended and restated from time to time. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name “Valiant Laboratories Limited” pursuant to certificate of incorporation dated August 16, 2021 issued by the by Central Registration Centre, Registrar of Companies. 

The company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. The company manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers. Paracetamol was initially approved by the U.S. Food and Drug Administration (USFDA) in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products.

The company was originally formed in year 1980 as a partnership firm under the Indian Partnership Act, 1932 under the name and style of ‘Bharat Chemicals’ and gradually, commenced manufacturing of Paracetamol by late 1982. In August 2021, its partnership firm was converted into a public limited company registered under the Companies Act. Its manufacturing facility is located at Plot nos. L-13 and L-30, Tarapur Industrial Area, Boisar, Palghar, in the state of Maharashtra, India. The company’s Manufacturing Facility employs modern machinery and equipment to ensure smooth flow of operations. It is holding certificate of good manufacturing practices (GMP) for manufacture and sale of bulk drugs / API and ISO 9001:2015 certification. Its quality control team monitors the manufacturing process at all stages from initial testing stage for incoming raw material to the final product prior to packing. 

Business area of the company

Valiant Laboratories is a leading Active Pharmaceutical ingredient manufacturing company with its focus on manufacturing Paracetamol API/Bulk Drug which has several applications like uses in treatment of conditions such as headache, muscle ache, arthritis, back ache, toothache, cold and fever. 

Key events and milestones

  • 1980: Formed Bharat Chemicals (a partnership firm).
  • 1981: Acquired plot No. L-30 in the Tarapur Industrial Area, Palghar, Maharashtra on leasehold basis admeasuring about 1,000 sq. mtrs.
  • 1982: Commenced manufacture of Paracetamol.
  • 2004-05: Acquired additional Plot Nos. L-28, L-28 (part), L-29 and L-13 at Tarapur Industrial Area, Palghar, Maharashtra collectively admeasuring about 3,000 sq. mtrs.
  • 2015: Annual revenue from operations crossed Rs 500 million.
  • 2021: Converted from partnership firm into a public limited company.
  • 2021: Annual revenue from operations crossed Rs 1,000 million.
  • 2022: Annual revenue from operations crossed Rs 2,000 million.
  • 2022: Formed wholly owned subsidiary, VASPL to diversify business activities.


Read More Read Less
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.